Astrazeneca Ab patents expiration
1. Breztri Aerosphere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
| US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8815258 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | |
| US11833292 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(14 years from now) | |
| US11331442 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
BREZTRI AEROSPHERE family patents
2. Bydureon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5424286 | ASTRAZENECA AB | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec, 2016
(7 years ago) | |
| US6858576 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Jan, 2017
(7 years ago) | |
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| US6495164 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6667061 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6479065 | ASTRAZENECA AB | Process for the preparation of polymer-based sustained release compositions |
Aug, 2020
(3 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US7223440 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Aug, 2021
(2 years ago) | |
|
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 6 months ago) | |
|
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(1 year, 18 days ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 8 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 11 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(4 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Reductions in bo...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON family patents
3. Bydureon Bcise patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| US6667061 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6479065 | ASTRAZENECA AB | Process for the preparation of polymer-based sustained release compositions |
Aug, 2020
(3 years ago) | |
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US7223440 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Aug, 2021
(2 years ago) | |
|
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 6 months ago) | |
|
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(1 year, 18 days ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 8 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 11 months from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
| US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(6 years from now) | |
|
US8895033 (Pediatric) | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| M(M-240) | Feb 15, 2022 |
| New Product(NP) | Oct 20, 2020 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: Reductions in body weight are observed with exenatide; Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4; As an adjunct to diet and exercise to imp...
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE family patents
4. Bydureon Pen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5424286 | ASTRAZENECA AB | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec, 2016
(7 years ago) | |
| US6858576 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Jan, 2017
(7 years ago) | |
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| US6667061 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6495164 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6479065 | ASTRAZENECA AB | Process for the preparation of polymer-based sustained release compositions |
Aug, 2020
(3 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US7223440 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Aug, 2021
(2 years ago) | |
|
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 6 months ago) | |
|
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(1 year, 18 days ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 8 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 11 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(3 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
|
US8758292 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(4 years from now) | |
|
US8216180 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(4 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(4 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
|
US9320853 (Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(4 years from now) | |
|
US8439864 (Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(4 years from now) | |
| US8827963 | ASTRAZENECA AB | Administering device with holding mechanism |
Feb, 2029
(4 years from now) | |
| US8690837 | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
May, 2029
(5 years from now) | |
|
US8827963 (Pediatric) | ASTRAZENECA AB | Administering device with holding mechanism |
Aug, 2029
(5 years from now) | |
|
US8690837 (Pediatric) | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
Nov, 2029
(5 years from now) | |
| US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
|
US8998876 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(6 years from now) | |
|
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| New Patient Population(NPP) | Jul 22, 2024 |
| M(M-240) | Feb 15, 2022 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| New Product(NP) | Jan 27, 2015 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Reductions in bo...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN family patents
5. Byetta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5424286 | ASTRAZENECA AB | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec, 2016
(7 years ago) | |
| US6858576 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Jan, 2017
(7 years ago) | |
| US7521423 | ASTRAZENECA AB | Exendin pharmaceutical compositions |
Oct, 2017
(6 years ago) | |
| US7297761 | ASTRAZENECA AB | Pharmaceutical compositions containing exendins |
Oct, 2017
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6902744 | ASTRAZENECA AB | Exendin agonist formulations and methods of administration thereof |
Jan, 2020
(4 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-232) | Nov 04, 2024 |
| M(M-148) | Nov 24, 2017 |
| M(M-113) | Oct 19, 2014 |
| M(M-111) | Oct 19, 2014 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 28 April, 2005
Treatment: Stimulating insulin release by administering exenatide; Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Use of exenatide may result in reduction in appetite.; Lowering...
Dosage: INJECTABLE;SUBCUTANEOUS
BYETTA family patents
6. Farxiga patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(11 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(4 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| US11826376 | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jul, 2039
(15 years from now) | |
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-834) | May 05, 2023 |
| M(M-212) | Oct 20, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-157) | Mar 11, 2018 |
| New Indication(I-841) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-r...
Dosage: TABLET;ORAL
FARXIGA family patents
7. Kombiglyze Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(3 years ago) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 05 November, 2010
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate; Method for treating type ii diabete...
Dosage: TABLET, EXTENDED RELEASE;ORAL
KOMBIGLYZE XR family patents
8. Onglyza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(3 years ago) | |
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-108) | Dec 16, 2014 |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 31 July, 2009
Treatment: Method for treating type ii diabetes by administering saxagliptin
Dosage: TABLET;ORAL
ONGLYZA family patents
9. Qtern patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-175) | Apr 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Strength(NS) | May 02, 2022 |
| New Indication(I-804) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
QTERN family patents
10. Qternmet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR family patents
11. Symlin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5686411 | ASTRAZENECA AB | Amylin agonist peptides and uses therefor |
Mar, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6608029 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2013
(10 years ago) | |
| US5814600 | ASTRAZENECA AB | Method and composition for treatment of insulin requiring mammals |
Sep, 2015
(8 years ago) | |
| US6114304 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2017
(6 years ago) | |
Drugs and Companies using PRAMLINTIDE ACETATE ingredient
Market Authorisation Date: 25 September, 2007
Treatment: Treatment of diabetes with an amylin agonist; Treatment of diabetes with an amylin agonist, including with insulin
Dosage: INJECTABLE;SUBCUTANEOUS
SYMLIN family patents
12. Xigduo Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(6 years from now) | |
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Indication(I-841) | Oct 18, 2022 |
| M(M-238) | Feb 22, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...
Dosage: TABLET, EXTENDED RELEASE;ORAL
XIGDUO XR family patents